The Oncology Institute, Inc. (TOI) Stock Score, Valuation & Financial Research
The Oncology Institute, Inc. is in the Healthcare sector and Medical - Care Facilities industry. It is reviewed using Wall Street Score's company-strength, valuation, growth and financial-health framework. The current Wall Street Score is 24/100.
Quick answer for TOI
The Oncology Institute, Inc. currently has a Wall Street Score of 24/100. The stored market price is $5.13. Its financial score is 25/100. Its valuation score is 0/100. The latest WSS change is +3.2 points. These figures are a research snapshot, not a buy or sell recommendation.
What The Oncology Institute, Inc. does
The Oncology Institute (TOI) is a specialized healthcare provider delivering a full range of medical oncology services throughout the United States. Its comprehensive offerings include direct physician care, integrated on-site infusion and medication dispensing facilities, and advanced clinical trial management. The institute also provides radiation therapy, specialized outpatient programs for stem cell transplants and transfusions, and robust patient support services. Furthermore, TOI is actively involved in operating palliative care initiatives and overseeing clinical trials. These services are specifically designed to meet the needs of adult and senior cancer patients. The company maintains a significant operational footprint with 67 clinic locations. The Oncology Institute was established in 2007 and is headquartered in Cerritos, California.
TOI financial snapshot
- Wall Street Score:
- 24/100
- Current price:
- $5.13
- Market capitalization:
- $512.9M
- Revenue:
- $587.2M
- Net income:
- $-36.3M
- Free cash flow:
- $-27.8M
- Cash:
- $41.1M
- Total debt:
- $24.6M
- EPS:
- -0.28
- Financial score:
- 25/100
- Valuation score:
- 0/100
- Revenue score:
- 47/100
What stands out
- Reported year-over-year revenue growth is +0.2%.
- Free cash flow is $-27.8M, showing cash burn in the current stored period.
- The balance sheet shows $41.1M of cash versus $24.6M of total debt, leaving more cash than debt.
- The latest Wall Street Score change is +3.2 points: TOI increased 3.2 points because Revenue improved by 7.8 points, Asset improved by 5.5 points, Management improved by 33.4 points.
- The current research record carries a share basis reconciled warning, which should be reviewed alongside the score.
What the numbers mean
Its current valuation score is 0/100, which Wall Street Score classifies as weak within the model's valuation framework.
The financial score is 25/100. This is a starting point for reviewing liquidity, leverage and cash-flow strength rather than a stand-alone recommendation.
A strong company and an attractive stock price are not always the same thing. Revenue, earnings, free cash flow, debt, management quality, competitive advantage and valuation should be considered together. Wall Street Score organizes these inputs into a consistent research framework so investors can identify what deserves deeper review.
Data freshness: Financial data last refreshed 2026-09-13.
How to research TOI
Start by understanding how the company makes money. Then compare revenue and earnings trends, cash generation, debt, liquidity and valuation. Review the company's latest filings and earnings reports before acting on any score or model estimate.
Learn how to analyze a stock · Read the Wall Street Score methodology · Browse other stocks
Data may change as company filings and market prices update. Educational research only; not a buy or sell recommendation.